BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35754396)

  • 1. Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity.
    Dorneles GP; Teixeira PC; da Silva IM; Schipper LL; Santana Filho PC; Rodrigues Junior LC; Bonorino C; Peres A; Fonseca SG; Monteiro MC; Boeck CR; Eller S; Oliveira TF; Wendland EM; Romão PRT
    J Cell Physiol; 2022 Aug; 237(8):3394-3407. PubMed ID: 35754396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
    Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
    Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
    Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
    Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical fitness modulates the expression of CD39 and CD73 on CD4
    Dorneles GP; da Silva IM; Peres A; Romão PRT
    J Cell Biochem; 2019 Jun; 120(6):10726-10736. PubMed ID: 30663116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
    Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
    Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.
    Pietrobon AJ; Andrejew R; Custódio RWA; Oliveira LM; Scholl JN; Teixeira FME; de Brito CA; Glaser T; Kazmierski J; Goffinet C; Turdo AC; Yendo T; Aoki V; Figueiró F; Battastini AM; Ulrich H; Benard G; Duarte AJDS; Sato MN
    Front Immunol; 2022; 13():1012027. PubMed ID: 36248842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine production by human B cells and B cell-mediated suppression of activated T cells.
    Saze Z; Schuler PJ; Hong CS; Cheng D; Jackson EK; Whiteside TL
    Blood; 2013 Jul; 122(1):9-18. PubMed ID: 23678003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
    Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
    Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus.
    Guzman-Flores JM; Cortez-Espinosa N; Cortés-Garcia JD; Vargas-Morales JM; Cataño-Cañizalez YG; Rodríguez-Rivera JG; Portales-Perez DP
    Immunobiology; 2015 Aug; 220(8):976-84. PubMed ID: 25770019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression.
    Schneider E; Winzer R; Rissiek A; Ricklefs I; Meyer-Schwesinger C; Ricklefs FL; Bauche A; Behrends J; Reimer R; Brenna S; Wasielewski H; Lauten M; Rissiek B; Puig B; Cortesi F; Magnus T; Fliegert R; Müller CE; Gagliani N; Tolosa E
    Nat Commun; 2021 Oct; 12(1):5911. PubMed ID: 34625545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
    Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
    Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
    Bönner F; Borg N; Burghoff S; Schrader J
    PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
    Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
    Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.